Zoliflodacin
Uncomplicated gonorrhea
Phase 3NDA Preparation
Key Facts
About Innoviva
Innoviva operates a dual-strategy business model, generating significant royalty revenue from its legacy respiratory assets partnered with GlaxoSmithKline (GSK), including TRELEGY ELLIPTA, ANORO ELLIPTA, and RELVAR/BREO ELLIPTA. This financial foundation supports its development of a diversified pipeline in areas of high unmet need, such as oncology and infectious diseases, through subsidiaries like Innoviva Specialty Therapeutics. The company's strategic focus is on acquiring and advancing late-stage clinical assets with the potential for near-term commercialization.
View full company profile